Wheeler Bio to Expand Biologic Manufacturing
Wheeler Bio, a CDMO specializing in antibody-based therapies, has closed a Series A-1 funding round led by Alloy Therapeutics and Echo Investment Capital, with support from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises. The funding will accelerate development through Wheeler’s Modular CMC platform and support its growing client base. The investment will also fund a new 52,000 sq. ft. large-scale biologics manufacturing facility in Oklahoma City’s Innovation District, adjacent to the Biomanufacturing Workforce Training Center (BioTC). The expansion reflects Wheeler’s continued commitment to innovation, community growth, and advancing the future of biologics production.
Wheeler Bio to Expand Biologic Manufacturing